Clinical Trial Update: Study of IK-595 in RAS- or RAF-altered Advanced Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of IK-595 in Ras- or Raf-altered advanced tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Malignant Glioma
• Malignant Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Thyroid Carcinoma

Drugs mentioned

• IK-595

Snippet

Sponsor: Ikena Oncology | Conditions: Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Status: TERMINATED